Iron Chelating Agents

• 

  Subject Areas on Research

  • A common duplication in the lysyl hydroxylase gene of patients with Ehlers Danlos syndrome type VI results in preferential stimulation of lysyl hydroxylase activity and mRNA by hydralazine. 
  • A multifunctional, light-activated prochelator inhibits UVA-induced oxidative stress. 
  • A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. 
  • Adherence to Iron Chelation Therapy with Deferasirox Formulations among Patients with Sickle Cell Disease and β-thalassemia. 
  • Brain temperature alters hydroxyl radical production during cerebral ischemia/reperfusion in rats. 
  • Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. 
  • Carrier-facilitated bulk liquid membrane transport of iron(III)-siderophore complexes utilizing first coordination sphere recognition. 
  • Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. 
  • Characterization of the aqueous iron(III) chelation chemistry of a potential Trojan Horse antimicrobial agent: chelate structure, stability and pH dependent speciation. 
  • Cold-induced brain edema in mice. Involvement of extracellular superoxide dismutase and nitric oxide. 
  • Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. 
  • Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone. 
  • Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. 
  • Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. 
  • Evidence for a low Km transporter for non-transferrin-bound iron in isolated rat hepatocytes. 
  • Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. 
  • Hypothesis: iron chelation plays a vital role in neutrophilic inflammation. 
  • Iron chelation equilibria, redox, and siderophore activity of a saccharide platform ferrichrome analogue. 
  • Iron chelation properties of an extracellular siderophore exochelin MN. 
  • Iron chelation properties of an extracellular siderophore exochelin MS. 
  • Iron homeostasis and eye disease. 
  • Iron overload and allogeneic hematopoietic stem-cell transplantation. 
  • Iron overload following red blood cell transfusion and its impact on disease severity. 
  • Kinetics of iron release from ferric binding protein (FbpA): mechanistic implications in bacterial periplasm-to-cytosol Fe3+ transport. 
  • Lead toxicity intervention in children. 
  • Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. 
  • Myelodysplastic syndromes. 
  • Novel gene functions required for melanization of the human pathogen Cryptococcus neoformans. 
  • Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. 
  • Oxalate deposition on asbestos bodies. 
  • Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. 
  • Prochelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation. 
  • Reactivation of Epstein-Barr Virus by HIF-1α Requires p53. 
  • Synthesis, siderophore activity and iron(III) chelation chemistry of a novel mono-hydroxamate, bis-catecholate siderophore mimic: N(alpha),-N(epsilon)-Bis[2,3-dihydroxybenzoyl]-l-lysyl-(gamma-N-methyl-N-hydroxyamido)-L-glutamic acid. 
  • Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina. 
  • Ternary complex formation facilitates a redox mechanism for iron release from a siderophore. 
  • The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. 
  • The influence of the synergistic anion on iron chelation by ferric binding protein, a bacterial transferrin. 
  • The kinetics of dimethylhydroxypyridinone interactions with iron(iii) and the catalysis of iron(iii) ligand exchange reactions: implications for bacterial iron transport and combination chelation therapies. 
  • The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. 
  • The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. 
  • The surface oxidation potential of melanosomes measured by free electron laser-photoelectron emission microscopy. 
  • Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention. 
  • Utilizing a Novel Mobile Health "Selfie" Application to Improve Compliance to Iron Chelation in Pediatric Patients Receiving Chronic Transfusions.